144
views
0
recommends
+1 Recommend
1 collections
    0
    shares
      scite_
       
      • Record: found
      • Abstract: found
      • Conference Proceedings: found
      Is Open Access

      Introducing LADR4 - A Platform Technology Solution to Make Drug Repurposing a Viable Solution

      Published
      conference-abstract
        1 ,
      REPO4EU
      RExPO23
      25-26 October 2023
      Drug repurposing, Generics, Rare diseases, LADR4
      Bookmark

            Abstract

            There are over 9,000 Rare Diseases with over 400M+ people affected and 90% diseases with no approved therapies. Repurposing can be a solution as it can cut the time to new therapies to <5 years and cost to more than 1/20 th of current projected costs of developing an NCE. Yet there is no significant effort on repurposing, the primary reason is that there is no security to investors due to lack of intellectual property protection.

            LADR 4 (Ligand Assisted Drug Repurposing Repositioning Rescuing and Reprofiling) provides this missing security to investors and hence can make repurposing a viable and sustainable effort to help address this significant gap of therapeutics for rare diseases. It allows for generic drugs to be re-patented under Composition of Matter claims and at the same time not requiring a full pre-clinical and clinical development by regulators. The most advanced drug using this platform is currently in Phase III trials in the US and Phase I trials in the UK.

            Additionally, four other US companies have licensed drugs based on this platform, two have gone public on the NASDAQ and PTOs in US, EU, China and Japan have issued Composition of Matter claims on drugs using this platform

            Finally, a solution to make repurposing viable and investable for patients and investors alike.

            Content

            Author and article information

            Conference
            REPO4EU
            8 September 2023
            Affiliations
            [1 ] Aayam Therapeutics;
            Author notes
            Author information
            https://orcid.org/0000-0002-9813-0844
            Article
            10.58647/REXPO.23000013.v1
            e47c4fcf-00b8-4a71-b61b-4fb95e1fee8d

            This work has been published open access under Creative Commons Attribution License CC BY 4.0 , which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. Conditions, terms of use and publishing policy can be found at www.scienceopen.com .

            RExPO23
            2
            Stockholm, Sweden
            25-26 October 2023
            History
            : 8 September 2023
            Categories

            Data sharing not applicable to this article as no datasets were generated or analysed during the current study.
            Medicine,Chemistry
            Drug repurposing,Generics,Rare diseases,LADR4

            Comments

            Comment on this article